Infectious Diseases

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS. All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is blinded independent central review (BICR)-verified progressive disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) after initial treatment.

2. A Study to Evaluate Biomarkers of Fluoroquinolone-induced Mitochondrial Toxicity

   Rochester, Minn.

   The purposes of this study are to determine if patients treated with fluoroquinolone (FQ) antibiotics have depletion of mitochondrial DNA (mtDNA) in buccal swab samples, and whether the degree of depletion correlates with the likelihood of developing FQ-associated toxicity.

   2nd arm - An additional group of patients will be enrolled if they previously received FQ antibiotics. appear to be symptomatic and have a previously collected muscle or nerve biopsy for clinical purposes available for this research study. 

3. A Study to Evaluate Lamprene (Clofazimine) to Treat Non-Tuberculous Mycobacterial (NTM) Infections

   Jacksonville, Fla.

   The purpose of this study is to  evaluate Lamprene (Clofazimine) to treat non-tuberculous mycobacterial (NTM) infections.

4. A Study to Collect Tissue, Fluids, Blood and/or Fungal Samples in Patients with Pulmonary and Extrapulmonary Coccidioidomycosis

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to create a biorepository of tissue, fluid and fungal specimens for future studies.

5. Molecular Analysis of Blood for the Detection of Cardiovascular Pathogens

   Rochester, Minn.

   The purpose of this study is to test whether metagenomic shotgun sequencing can identify pathogens causing cardiovascular infections such as infective endocarditis or myocarditis.

6. A Study to Evaluate the QuantiFERON-TB Gold-Plus Test for Blood Detection of Tuberculosis without Symptoms

   Rochester, Minn.

   The purpose of this study is to evaluate the new QFT-Plus assay compared to the QFT-Gold assay and the tuberculin skin test results (as available) for the detection of tuberculosis without symptoms in high-risk patients.

                  

7. COVID-19 (Coronavirus) Pandemic on Health and Healthcare

   Rochester, Minn.

   The purpose of this study is to identify correlates of healthcare-seeking behavior in patients with ACS and CHF and its association with psychosocial and health outcomes.

8. RLY-2608-201-Ph2 Study of RLY-2608 in PROS and PIK3CA Driven Malformations

   Rochester, Minn.

   The purpose of this study is to compare the efficacy and safety of RLY-2608 versus placebo in adult, adolescent, and pediatric participants with PROS and malformations driven by PIK3CA mutations, which is preceded by a dose selection and basket design with exploratory single-arm cohorts for various subpopulations of participants.

9. Infection Database of Mechanical Circulatory Assist Device Recipients

   Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to learn more about incidence of infection complications in recipients of mechanical circulatory assist device recipients (MCAD).  Evaluate morbidity and mortality associated with infection complications in MCAD recipients.

10. Lymphoid Tissue Examination

    Rochester, Minn.

    The purpose of this study is to study HIV infected individuals or others who have had another infection or inflammatory condition that may affect the content or structure of lymph nodes or may have none of these conditions and the sample will be used as a normal control.